Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia

Published:2011-05-23 Issue:6 Volume:52 Page:1055-1065
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Pileckyte Regina,Jurgutis Mindaugas,Valceckiene Vilma,Stoskus Mindaugas,Gineikiene Egle,Sejoniene Jurgita,Degulys Andrius,Zvirblis Tadas,Griskevicius Laimonas

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.562572

Reference27 articles.

1. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia

2. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

3. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

4. Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

5. High Dose Methyl Prednisolone in Refractory Chronic Lymphocytic Leukaemia

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia;European Journal of Clinical Investigation;2020-10-22

2. Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors;Advances in Medical Sciences;2020-09

3. Chronic Lymphocytic Leukemia;Abeloff's Clinical Oncology;2020

4. Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia;Medicina;2019-10-29

5. Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review;Journal of Hematology;2019